Mirova’s Takeda Pharmaceutical TAK Stock Holding History

Mirova’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,301	Closed	-$22K	–	189
2019 Q3	$22K	Buy	+1,301	New	+$22.5K	﹤0.01%	124

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Mirova's TAK Position: Q4 2019 in Review

Mirova sold out of Takeda Pharmaceutical (TAK) in Q4 2019, closing a stake of 1,301 shares — an estimated $22K sold.

Mirova first reported a position in TAK in Q3 2019 and held it in 1 quarter. The position peaked at $22K in Q3 2019. 339 funds tracked by Wall St. Rank hold TAK as of Q4 2019.

Mirova reported no remaining Takeda Pharmaceutical position as of Q4 2019 after selling out during the quarter.
Mirova sold 1,301 Takeda Pharmaceutical shares in Q4 2019, an estimated $22K.
Mirova first reported a position in Takeda Pharmaceutical in Q3 2019 and held it in 1 quarter.
Mirova's Takeda Pharmaceutical position peaked at $22K in Q3 2019.
339 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2019.

Based on Mirova's 13F filing for Q4 2019, filed 14 Feb 2020.